ELISpot and FluoroSpot are perfect potency assays for cell and gene therapy development. They offer critical insights into CAR-T cell functionality, TIL activity, cancer vaccine efficacy, and gene therapy using AAV or other viral vectors. With the FDA's recommendations on using cytokine secretion assays, ensure your therapy's path to success is clearly mapped with ELISpot and FluoroSpot.
ELISpot is an immunoassay used to quantify cytokine-secreting cells, and FluoroSpot is the multiplex-version of the same assay. In these sandwich assays, target cytokines secreted by cells are captured by specific antibodies immediately after secretion and throughout the stimulation process, making them extremely sensitive. For this reason, ELISpot and FluoroSpot also lend themselves very well to immunogenicity assays in cell- and gene therapy settings.
In this webinar, we go through:
- the assay principles of ELISpot and FluoroSpot
- their features and advantages over, for example, flow cytometry
- and present use cases in which FluoroSpot and ELISpot have been utilized to gain functional data of CAR T cells, cancer vaccines, and tumor-infiltrating lymphocytes.
Presenter
Jens Gertow, CCO at Mabtech, holds a PhD in immunology from Karolinska Institutet.
The presentation is followed by a Q&A session with:
Maria Karvouni, PhD, Field Application Specialist
Esther Schoutrop, PhD, Field Application Specialist